Individualizing Antiretroviral Therapy on the Basis of Comorbidities and the Risk for Viral Resistance CME

Author Information and Disclosures

Release Date: April 30, 2008; Valid for credit through April 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
GlaxoSmithKline
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Summarize the DHHS and IAS-USA guidelines for instituting antiretroviral therapy (ART) in light of the potential comorbidities of individual and combination antiretroviral agents.
  2. Demonstrate expertise in utilizing genotypic and/or phenotypic resistance testing to choose appropriate combination ART.
  3. Discuss the relative advantages of NNRTI-based and PI-based antiretroviral combination regimens in the treatment of HIV.
Authors and Disclosures

Martin S. Hirsch, MD
Disclosure: Martin S. Hirsch, MD, has disclosed that he has served as a consultant to Merck.


Judith E. Feinberg, MD
Disclosure: Judith E. Feinberg, MD, has disclosed that she has received grants for clinical research from Tibotec, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Koronis, Bioavailability Systems, Theratechnology, Achillion, NeurogesX, and Panacos. Dr. Feinberg has also disclosed that she has received grants for educational activities from Tibotec, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Abbott, Pfizer, and Merck, and that she has served as an advisor or consultant to Tibotec, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck, and Koronis. Dr. Feinberg has also disclosed that she is the Data and Safety Monitoring Board Chair for Panacos.


Thomas Maxwell Mundy, MD
Disclosure: Thomas Maxwell Mundy, MD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.